Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity

Sophia El Hamichi, Khushi Saigal, Estephania Feria Anzaldo, Aaron Gold, Audina M. Berrocal, Timothy G. Murray

Research output: Contribution to journalArticlepeer-review


A 23-month-old girl born at 23 weeks' gestational age with a birth weight of 453 g and retinopathy of prematurity (ROP) stage 4A in 360° and plus disease in both eyes was treated in another institution with laser; her treatment was complicated with two cardiac arrests during the procedure. The patient was referred and treated at 31 weeks with repeated intravitreal bevacizumab injection in both eyes secondary to progressive ROP. Treatment with multiple anti-vascular endothelial growth factor (VEGF) therapy as monotherapy led to the resolution of a retinal detachment and full vascularization of the retina in both eyes. To the best of the authors' knowledge, this is the first description of a patient with stage 4A ROP treated solely with anti-VEGF after failed laser treatment that led to complete resolution of a retinal detachment without surgical intervention. [Ophthalmic Surg Lasers Imaging Retina. 2022;53:159-163.].

Original languageEnglish (US)
Pages (from-to)159-163
Number of pages5
JournalOphthalmic surgery, lasers & imaging retina
Issue number3
StatePublished - Mar 1 2022

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity'. Together they form a unique fingerprint.

Cite this